GHK-Cu

GHK-Cu combines the tripeptide glycyl-histidyl-lysine with copper. Coordination is the binding of a metal ion to groups on the peptide. The blue colour is a useful observation, but it cannot establish the complete identity or purity of a batch.

The earlier page discusses terminal forms without consistently separating their specifications. The intended GHK form must therefore be established from the actual sequence specification and analytical record. Its resin and release tables are inherited examples, not proof of a particular terminal form.

The described process first assembles the GHK chain with protected amino acids. Histidine protection and coupling conditions matter because unwanted changes can alter the later copper-binding material. Cleavage removes the chain from the support and releases the protected side chains.

Copper complex formation is a distinct operation. The older account compares copper salts and tracks pH, mixing, temperature and the copper-to-peptide ratio. Those variables affect whether the record describes the intended complex, excess free copper or material lost through precipitation.

The earlier route uses chromatographic separation to address uncomplexed peptide, deletion products and other residues. Separation conditions need to preserve the form being measured; a method that changes the complex cannot by itself describe the starting mixture.

Fraction pooling, solvent removal and counterion exchange need to be linked to a final identity check. The technical appendix retains the old example parameters. They should be assessed alongside the actual complex’s behaviour rather than treated as a universal purification recipe.

Mass, chromatographic behaviour and composition address peptide identity. Copper measurement by elemental analysis answers another question: how much metal is present. The amount of copper and the proportion bound in the intended form should not be treated as interchangeable results.

The earlier panel also covers water, counterions, residual solvents, related substances and microbial quality. A batch certificate needs actual results and method references for the claims it makes. Neither colour nor a single HPLC peak establishes all of them.

The older stability account highlights copper dissociation, where the metal separates from the peptide, alongside chemical degradation. Light, moisture, pH and the container can change the mixture. A stability method needs to distinguish those changes rather than report colour alone.

Frozen, refrigerated and room-temperature studies are retained as study topics. Their example schedules do not establish shelf life for a new formulation. Cleaning and handling controls also need to address copper-containing residues between batches.

The record should distinguish peptide synthesis, complex formation, purification and final release. It should include the copper source, raw-material lots, in-process observations, cleaning checks, calibration, deviations and change control. Equipment qualification and process validation address different parts of this chain.

On FDA’s page current as of April 22, 2026, GHK-Cu for injectable routes is listed among substances nominated but withdrawn. Withdrawal is not clearance. Topical cosmetic use is a separate regulatory context; a cosmetic ingredient is not an FDA-approved injectable drug.

GHK-Cu tables retain the earlier manufacturing examples. No GHK-Cu table here validates an operating procedure, release limit or supplier result. The GHK-Cu examples have no supporting batch raw data; use them to identify document fields, not to infer measured performance.

GHK-Cu source links are retained below. These references give context for GHK-Cu manufacturing; they do not validate the numerical examples. Duplicate GHK-Cu source links retain the citation record.

1. Oath Research
2. Valeur, E., & Bradley, M. (2009). Amide bond formation: beyond the myth of coupling reagents. Chemical Society Reviews, 38(2), 606-631. https://doi.org/10.1039/B701677H
3. Albericio, F., Bofill, J. M., El-Faham, A., & Kates, S. A. (1998). Use of onium salt-based coupling reagents in peptide synthesis. Journal of Organic Chemistry, 63(26), 9678-9683. https://doi.org/10.1021/jo980807y
4. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987
5. Mant, C. T., & Hodges, R. S. (2008). High-Performance Liquid Chromatography of Peptides and Proteins: Separation, Analysis, and Conformation. CRC Press. https://doi.org/10.1201/9781420027624
6. International Council for Harmonisation (ICH). (2005). Validation of Analytical Procedures: Text and Methodology Q2(R1). https://www.ich.org/page/quality-guidelines
7. United States Pharmacopeia. (2023). General Chapter <233> Elemental Impurities—Procedures. USP-NF. https://www.usp.org/harmonization-standards/pdg/general-chapters/elemental-impurities
8. International Council for Harmonisation (ICH). (2003). Stability Testing of New Drug Substances and Products Q1A(R2). https://www.ich.org/page/quality-guidelines
9. Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 27(4), 544-575. https://doi.org/10.1007/s11095-009-0045-6
10. U.S. Food and Drug Administration. (2011). Process Validation: General Principles and Practices. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices
11. U.S. Food and Drug Administration. (1993). Guide to Inspections of Validation of Cleaning Processes. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/validation-cleaning-processes-1993